Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by HighteawithIntrepidon Oct 17, 2017 4:51pm
202 Views
Post# 26823118

China money

China moneyFrom the Q2 statement subsequent events:
On August 11, 2017, the Corporation entered into definitive agreements with affiliates of Shenzhen Royal Asset Management Co., Ltd. (collectively “SRAM”) to develop and commercialize PBI-4050, PBI-4547 and PBI-4425 in the People’s Republic of China (excluding Hong Kong, Taiwan and Macau). Under the agreements, SRAM will pay the Corporation an upfront payment of $13.0 million (US$10.0 million) and a first milestone payment of $9.1 million (US$7.0 million), as well as a further $10.5 million (US$8.0 million) over the following years based on completion of further development and regulatory milestones. 

so no way it’s all in the bank, so we have going concern issues and that is why the market has discounted our future vouchers. So PL let’s do the rights offering already.
Bullboard Posts